Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CMA1 | P23946 | 1/20 | 0.31 |
| ▸ | HPD | P32754 | 2/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6678209 | 0.89 | ALDH1A1 (0.38) | MEN1CYP3A4CYP2C9KMT2AGAA | |
| SCHEMBL6683575 | 0.84 | GAA (0.46) | MEN1CYP3A4CYP2C9KMT2AGAA | |
| SCHEMBL6678802 | 0.79 | CMA1 (0.31) | CMA1PKMRAB9ASMN1; SMN2 | |
| SCHEMBL7058690 | 0.78 | GAA (0.34) | MEN1CYP3A4CYP2C9KMT2AGAA | |
| SCHEMBL7061584 | 0.77 | MEN1 (0.32) | MEN1CYP3A4CYP2C9KMT2AGAA | |
| SCHEMBL6683259 | 0.75 | ALDH1A1 (0.35) | KMT2AL3MBTL1ALDH1A1PKMNPSR1 | |
| SCHEMBL7057681 | 0.70 | CMA1 (0.30) | CMA1 | |
| SCHEMBL6678368 | 0.68 | MEN1 (0.41) | MEN1CYP3A4CYP2C9KMT2AGAA | |
| SCHEMBL6664692 | 0.68 | GAA (0.30) | GAALMNAHTT | |
| SCHEMBL6680501 | 0.68 | PTGS1 (0.34) | L3MBTL1ALDH1A1PKMRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040224951-A1 | 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | ROARK WILLIAM HOWARD (US) | 2004-11-11 | — | — | US | disclosed |
| WO-2004014921-A1 | 5,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224951-A1 | 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | MMP9, MMP13, MMP25 | MEN1 3549/4885CYP3A4 1686/4885CYP2C9 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.